MULTIPLE SCLEROSIS (MS) PRACTICE TEST (SAMPLE)

STUDY GUIDE



SAMPLE STUDY GUIDE WITH LIMITED QUESTIONS

VISIT US ONLINE FOR THE FULL VERSION STUDY GUIDE

https://multiplesclerosis.examzify.com

Copyright © 2026 by Examzify - A Kaluba Technologies Inc. product.

ALL RIGHTS RESERVED.

No part of this book may be reproduced or transferred in any form or by any means, graphic, electronic, or mechanical, including photocopying, recording, web distribution, taping, or by any information storage retrieval system, without the written permission of the author.

Notice: Examzify makes every reasonable effort to obtain accurate, complete, and timely information about this product from reliable sources.

SAMPLE

Table of Contents

Copyright 1

Table of Contents 2

Introduction 3

How to Use This Guide 4

Questions 5

Answers 8

Explanations 10

Next Steps 15

SAMPLE

Introduction

Preparing for a certification exam can feel overwhelming, but with the right tools, it becomes an opportunity to build confidence, sharpen your skills, and move one step closer to your goals. At Examzify, we believe that effective exam preparation isn't just about memorization, it's about understanding the material, identifying knowledge gaps, and building the test-taking strategies that lead to success.

This guide was designed to help you do exactly that.

Whether you're preparing for a licensing exam, professional certification, or entry-level qualification, this book offers structured practice to reinforce key concepts. You'll find a wide range of multiple-choice questions, each followed by clear explanations to help you understand not just the right answer, but why it's correct.

The content in this guide is based on real-world exam objectives and aligned with the types of questions and topics commonly found on official tests. It's ideal for learners who want to:

- Practice answering questions under realistic conditions,
- Improve accuracy and speed,
- Review explanations to strengthen weak areas, and
- Approach the exam with greater confidence.

We recommend using this book not as a stand-alone study tool, but alongside other resources like flashcards, textbooks, or hands-on training. For best results, we recommend working through each question, reflecting on the explanation provided, and revisiting the topics that challenge you most.

Remember: successful test preparation isn't about getting every question right the first time, it's about learning from your mistakes and improving over time. Stay focused, trust the process, and know that every page you turn brings you closer to success.

Let's begin.

SAMPLE

How to Use This Guide

This guide is designed to help you study more effectively and approach your exam with confidence. Whether you're reviewing for the first time or doing a final refresh, here's how to get the most out of your Examzify study guide:

1. Start with a Diagnostic Review

Skim through the questions to get a sense of what you know and what you need to focus on. Your goal is to identify knowledge gaps early.

2. Study in Short, Focused Sessions

Break your study time into manageable blocks (e.g. 30 – 45 minutes). Review a handful of questions, reflect on the explanations.

3. Learn from the Explanations

After answering a question, always read the explanation, even if you got it right. It reinforces key points, corrects misunderstandings, and teaches subtle distinctions between similar answers.

4. Track Your Progress

Use bookmarks or notes (if reading digitally) to mark difficult questions. Revisit these regularly and track improvements over time.

5. Simulate the Real Exam

Once you're comfortable, try taking a full set of questions without pausing. Set a timer and simulate test-day conditions to build confidence and time management skills.

6. Repeat and Review

Don't just study once, repetition builds retention. Re-attempt questions after a few days and revisit explanations to reinforce learning. Pair this guide with other Examzify tools like flashcards, and digital practice tests to strengthen your preparation across formats.

There's no single right way to study, but consistent, thoughtful effort always wins. Use this guide flexibly, adapt the tips above to fit your pace and learning style. You've got this!

SAMPLE

Questions

SAMPLE

1. When is plasmapheresis indicated in MS?

A. If no significant improvement after 3–5 days of high-dose steroids in an acute relapse.

B. After 24 hours of high-dose steroids in any relapse.

C. Only after failure of all other therapies.

D. In every relapse alongside steroids.

2. Which statement best describes relapse pattern in Relapsing-Remitting MS?

A. No relapses, steady progression.

B. Attacks always lead to complete disability.

C. Progression only during sleep.

D. Discrete attacks with full or partial recovery between attacks.

3. In spinal MS lesions, what lesion length pattern helps differentiate from NMOSD?

A. MS lesions are short (1–2 vertebral segments)

B. NMOSD lesions are short

C. Spinal MS lesions longer than 5 segments

D. No typical pattern between the two conditions

4. Which of the following is a clinical manifestation of advanced MS?

A. Visual involvement

B. Intention tremor

C. Spastic paraplegia or quadriplegia

D. Dysarthria

5. Name an MRI feature that is particularly supportive of MS diagnosis.

A. Presence of multiple periventricular lesions with Dawson fingers and involvement of juxtacortical regions, as well as asymmetrical spinal cord lesions

B. Isolated brainstem diffusion restriction

C. Meningeal enhancement without parenchymal lesions

D. Normal MRI with no lesions

SAMPLE

6. Name two core immunopathologic processes in MS.

A. Vascular occlusion causing ischemia.

B. Autoimmune demyelination mediated by autoreactive T cells and B cells leading to focal plaques and secondary axonal injury.

C. Neuron loss from tau tangles.

D. Infectious demyelination due to a single virus.

7. What is the mechanism of action of ocrelizumab?

A. It inhibits S1P receptors

B. It targets CD20-positive B cells

C. It antagonizes integrins

D. It modulates T cells via CTLA-4

8. Name the main MS disease courses and a defining feature of each.

A. Relapses with continuous progression from onset.

B. Relapsing-remitting MS with discrete attacks and full or partial recovery.

C. CIS with always progression.

D. Single episode with no chance of MS.

9. Relapsing-remitting MS is defined by which pattern?

A. Intermittent relapses with full remission

B. Progressive worsening from onset

C. Relapses with attack symptoms and remission

D. Stable disease with no relapses

10. Which group of viruses has been hypothesized to be involved in multiple sclerosis?

A. Influenza

B. Measles

C. Herpes simplex virus

D. Influenza, measles, and herpes simplex virus

SAMPLE

Answers

SAMPLE

1. A
2. D
3. A
4. C
5. A
6. B
7. B
8. B
9. C
10. D

SAMPLE

Explanations

SAMPLE

1. When is plasmapheresis indicated in MS?

A. If no significant improvement after 3–5 days of high-dose steroids in an acute relapse.

B. After 24 hours of high-dose steroids in any relapse.

C. Only after failure of all other therapies.

D. In every relapse alongside steroids.

Plasmapheresis is a second-line option for an acute MS relapse when steroids don't produce a meaningful improvement. After a standard course of high dose IV steroids (typically 3–5 days), if there's no significant improvement, plasma exchange can be started. It helps by removing circulating autoantibodies and inflammatory mediators, which can rapidly reduce CNS inflammation and hasten recovery. For best results, begin within about 10 days of relapse onset. This approach is not used after just 24 hours of steroids, not required for every relapse, and not something that's done only after every other therapy has failed.

2. Which statement best describes relapse pattern in Relapsing-Remitting MS?

A. No relapses, steady progression.

B. Attacks always lead to complete disability.

C. Progression only during sleep.

D. Discrete attacks with full or partial recovery between attacks.

Relapsing-Remitting MS is defined by discrete attacks of new or worsening neurologic symptoms, each lasting at least 24 hours, with periods of recovery in between. Between these relapses, the course is not steadily progressive—patients may recover fully or partially after each attack, leaving no permanent progression during the remission intervals. This pattern—clear episodes of relapse followed by improvement or stability between them—is the hallmark distinguishing RRMS from progressive forms. The idea that relapses always cause complete disability, or that progression occurs only during sleep, doesn't fit how RRMS typically behaves; instead, the key is attacks with recovery between them.

3. In spinal MS lesions, what lesion length pattern helps differentiate from NMOSD?

A. MS lesions are short (1–2 vertebral segments)

B. NMOSD lesions are short

C. Spinal MS lesions longer than 5 segments

D. No typical pattern between the two conditions

The main idea is that lesion length on spinal MRI helps distinguish MS from NMOSD. MS typically produces short, focal spinal lesions, about 1–2 vertebral segments in length. In contrast, NMOSD commonly presents with longitudinally extensive lesions that span 3 or more segments. So recognizing a short lesion pattern supports MS rather than NMOSD. That's why the statement that MS lesions are short (1–2 vertebral segments) is the best choice. If a lesion extends over many segments, NMOSD would be more likely.

SAMPLE

4. Which of the following is a clinical manifestation of advanced MS?

A. Visual involvement

B. Intention tremor

C. Spastic paraplegia or quadriplegia

D. Dysarthria

Advanced MS is marked by widespread motor system involvement. When the disease progresses to this stage, destruction of the corticospinal tracts leads to spasticity and weakness that can become profound in the legs (spastic paraplegia) and, as it advances further, in the arms and legs together (quadriplegia). This pattern reflects extensive demyelination and axonal loss in motor pathways, signaling severe, progressive disability. Other symptoms like visual loss from optic neuritis or speech problems can occur at various stages, and tremor or dysarthria may appear as well, but the clear, defining feature of advanced disease is the development of substantial spastic weakness in the limbs, especially progressing to paraplegia or quadriplegia.

5. Name an MRI feature that is particularly supportive of MS diagnosis.

A. Presence of multiple periventricular lesions with Dawson fingers and involvement of juxtacortical regions, as well as asymmetrical spinal cord lesions

B. Isolated brainstem diffusion restriction

C. Meningeal enhancement without parenchymal lesions

D. Normal MRI with no lesions

The key idea is that MRI findings in multiple sclerosis reflect demyelinating plaques that preferentially involve periventricular white matter and areas adjacent to the cortex, with spinal cord involvement that can be asymmetric. The most characteristic pattern is multiple periventricular lesions that extend outward from the ventricles in a finger-like appearance called Dawson fingers. This pattern arises because demyelination tracks along small veins near the ventricles, creating lesions that run perpendicular to the ventricular system. When you add involvement of juxtacortical regions (areas right next to the cortex) and show spinal cord lesions that are, often, asymmetric, you have a combination that is highly supportive of MS in the right clinical context. Other patterns like isolated brainstem diffusion restriction are more typical of acute stroke or other processes, meningeal enhancement without true parenchymal lesions is not characteristic of classic MS, and a completely normal MRI would argue against MS (since dissemination in space is expected to be visible as the disease evolves).

6. Name two core immunopathologic processes in MS.

A. Vascular occlusion causing ischemia.

B. Autoimmune demyelination mediated by autoreactive T cells and B cells leading to focal plaques and secondary axonal injury.

C. Neuron loss from tau tangles.

D. Infectious demyelination due to a single virus.

In MS, the immune system targets the central nervous system myelin, producing inflammatory demyelination and, over time, axonal injury. The two main immunopathologic processes are autoimmune demyelination mediated by autoreactive T cells and B cells, which leads to focal plaques in the CNS, and the secondary axonal injury that follows demyelination as neurons lose protective myelin and signaling becomes disrupted. T cells help drive the inflammatory response, while B cells contribute by producing autoantibodies and presenting antigen, sustaining inflammation and contributing to lesion development. This combination results in demyelinating plaques with eventual axonal loss, which underpins the disability seen in MS. The other options don't fit this pattern: vascular occlusion isn't the primary driver in MS, neuron loss from tau tangles is more typical of tauopathies like Alzheimer's disease, and infectious demyelination from a single virus does not capture the autoimmune, multi-cellular attack seen in MS.

SAMPLE

7. What is the mechanism of action of ocrelizumab?

A. It inhibits S1P receptors

B. It targets CD20-positive B cells

C. It antagonizes integrins

D. It modulates T cells via CTLA-4

The mechanism being tested is that ocrelizumab targets CD20 on B cells, leading to their depletion. By binding CD20, it eliminates mature B cells through processes like antibody-dependent cellular cytotoxicity and complement-mediated cytotoxicity. This reduces B cell–mediated antigen presentation and pro-inflammatory cytokine production, which lowers CNS autoimmune activity in multiple sclerosis. Since CD20 is not on stem cells or plasma cells, the immune system can gradually recover B cells and continue producing antibodies, though overall B-cell numbers are reduced for a period after treatment. Ocrelizumab is used for relapsing MS and primary progressive MS, with infusions given every six months after the initial doses. Other options describe different mechanisms (S1P receptor inhibition, integrin blockade, or T-cell co-stimulation modulation) that do not explain how ocrelizumab works.

8. Name the main MS disease courses and a defining feature of each.

A. Relapses with continuous progression from onset.

B. Relapsing-remitting MS with discrete attacks and full or partial recovery.

C. CIS with always progression.

D. Single episode with no chance of MS.

Relapsing-remitting MS is defined by clearly separated attacks (relapses) followed by periods of recovery, which can be full or partial. This pattern—episodes of new or worsened symptoms that come and go with stable function between attacks—gives RRMS its distinct course among MS types. The statement matches RRMS because it emphasizes discrete attacks and recovery between them. Other MS courses describe different evolution: a progression from the start with little to no relapse activity fits primary progressive MS, while a course that begins with relapse-relapse and then shifts to a gradual progression fits secondary progressive MS. Clinically isolated syndrome is a first MS-like event that may or may not progress to full MS, so it isn't characterized by a defined, ongoing relapse-remission pattern. A single episode with no chance of MS isn't accurate because CIS carries a real risk of converting to MS in many patients. So the best answer captures the hallmark of RRMS: discrete attacks with potential full or partial recovery between attacks.

9. Relapsing-remitting MS is defined by which pattern?

A. Intermittent relapses with full remission

B. Progressive worsening from onset

C. Relapses with attack symptoms and remission

D. Stable disease with no relapses

Relapsing-remitting MS shows episodes of new or worsening neurologic symptoms caused by inflammatory activity, called relapses, followed by periods of recovery or return toward baseline, called remissions. Between relapses there is no continuous worsening, so the disease isn't steadily progressive. This episodic pattern—attacks followed by improvement—is what sets RRMS apart from other MS courses where disability accumulates without distinct relapses (primary progressive MS) or where relapses may be followed by incomplete recovery and the disease remains active in a progressive way (secondary progressive forms). So the description of relapses with attack symptoms and remission best captures the relapsing-remitting pattern. It's worth noting that recovery after a relapse can be partial; complete remission isn't guaranteed, which is why the emphasis is on relapses plus remission rather than a promise of full, unbroken recovery.

SAMPLE

10. Which group of viruses has been hypothesized to be involved in multiple sclerosis?

A. Influenza

B. Measles

C. Herpes simplex virus

D. Influenza, measles, and herpes simplex virus

Viral infections have long been considered potential triggers for multiple sclerosis, so researchers have explored whether more than one virus could be involved. In MS research, several viruses have been studied as possible triggers, including influenza, measles, and herpes simplex virus. The option that includes all three best captures this broad, multi-virus hypothesis, which is why it is the most appropriate choice. It's also helpful to know that later work has highlighted other viruses (like Epstein-Barr virus) as having a strong association with MS, but the idea that multiple viruses could contribute to MS risk remains a common part of the discussion.

SAMPLE

Next Steps

Congratulations on reaching the final section of this guide. You've taken a meaningful step toward passing your certification exam and advancing your career.

As you continue preparing, remember that consistent practice, review, and self-reflection are key to success. Make time to revisit difficult topics, simulate exam conditions, and track your progress along the way.

If you need help, have suggestions, or want to share feedback, we'd love to hear from you. Reach out to our team at hello@examzify.com.

Or visit your dedicated course page for more study tools and resources:

https://multiplesclerosis.examzify.com

We wish you the very best on your exam journey. You've got this!

SAMPLE